Reminder Emails to Improve Pneumococcal Vaccine Completion at 12 Months of Age

Not Applicable

Recruiting

• Conditions: Immunization Coverage; Pneumococcal Vaccines

• Registration Number: NCT06000397
• Lead Sponsor: Ottawa Hospital Research Institute

Brief Summary

The goal of this clinical trial is to assess the effectiveness of enhanced email reminders in improving vaccine coverage at the 12-month visit in CANImmunize app users. The main questions it aims to answer are:

* Do enhanced email reminders improve coverage of the 12- month dose of the pneumococcal vaccine and the timely completion of its immunization series at the 12-month's visit in CANImmunize app users?

* What are the predictors of predictors of timely completion of the 12-month's series of pneumococcal vaccines in the CANImmunize app users?

Participants will be randomized to either receive enhanced reminder/recall materials via email or the standard CANImmunize notifications. Researchers will compare the enhanced reminder group to the standard notification group to see if there is a difference in vaccine coverage at the 12-month visit.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-08-14
• Study First Submitted QC: 2023-08-14
• Study First Posted: 2023-08-21
• Study Start: 2023-11-07
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-08
• Last Update Posted: 2024-04-09
• Primary Completion: 2024-06
• Study Completion: 2024-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Receipt of 12-month pneumococcal vaccine	12 months of age	Receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record

Secondary Outcome Measures

Name	Time	Method
Timeliness of 12-month pneumococcal vaccine	12-13 months of age will be considered as timely, after 13 months considered late	Age at receipt of the 12-month dose of the pneumococcal vaccine as recorded in the CANImmunize immunization record

Trial Locations

Locations (1)

CANImmunize; 🇨🇦 Ottawa, Canada